Orchid Pharma Ltd Stock Price Today (NSE: ORCHPHARMA)
Fundamental Score
Orchid Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Orchid Pharma Ltd share price today is ₹986.55, down 1.37% on NSE/BSE as of 31 July 2026. Orchid Pharma Ltd (ORCHPHARMA) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹5.60K (Cr). The 52-week high for ORCHPHARMA share price is ₹1119.80 and the 52-week low is ₹480.00. At a P/E ratio of 206.31x, ORCHPHARMA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 2.12% and a debt-to-equity ratio of 0.28.
Orchid Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Orchid Pharma Ltd share price chart: 1.21% return over the past month. 52-week high ₹1119.80, 52-week low ₹480.00.
Orchid Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹995.20 | ₹1004.95 | ₹983.20 | ₹986.55 | 29.85K (Cr) | |
| ₹1004.00 | ₹1009.00 | ₹982.25 | ₹1000.25 | 36.31K (Cr) | |
| ₹982.10 | ₹1022.00 | ₹982.10 | ₹1001.45 | 47.13K (Cr) | |
| ₹987.30 | ₹992.00 | ₹968.10 | ₹985.35 | 43.88K (Cr) | |
| ₹995.00 | ₹1006.10 | ₹979.95 | ₹987.95 | 45.69K (Cr) | |
| ₹966.00 | ₹999.00 | ₹951.95 | ₹988.60 | 51.06K (Cr) | |
| ₹1047.00 | ₹1047.00 | ₹1007.30 | ₹1023.00 | 79.98K (Cr) | |
| ₹1049.00 | ₹1066.50 | ₹1042.40 | ₹1046.60 | 56.31K (Cr) | |
| ₹1084.30 | ₹1084.30 | ₹1027.10 | ₹1041.35 | 1.22L (Cr) | |
| ₹1119.80 | ₹1119.80 | ₹1067.60 | ₹1078.95 | 1.47L (Cr) |
Orchid Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹979.95 | ₹1119.80 | ₹916.75 | ₹986.55 | +0.67% | |
| ₹812.45 | ₹1094.00 | ₹764.05 | ₹972.80 | +19.74% | |
| ₹625.75 | ₹828.00 | ₹617.50 | ₹792.50 | +26.65% | |
| ₹494.00 | ₹629.95 | ₹488.50 | ₹625.75 | +26.67% | |
| ₹614.00 | ₹617.40 | ₹480.00 | ₹482.45 | -21.43% | |
| ₹693.70 | ₹719.80 | ₹616.00 | ₹619.75 | -10.66% | |
| ₹767.45 | ₹805.00 | ₹672.00 | ₹699.10 | -8.91% | |
| ₹837.35 | ₹875.70 | ₹745.20 | ₹758.95 | -9.36% | |
| ₹715.00 | ₹899.00 | ₹715.00 | ₹833.20 | +16.53% | |
| ₹703.00 | ₹755.00 | ₹701.00 | ₹726.30 | +3.31% | |
| ₹735.00 | ₹793.95 | ₹695.60 | ₹702.00 | -4.49% | |
| ₹777.40 | ₹816.25 | ₹720.00 | ₹734.05 | -5.58% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Overvalued turnaround story with deteriorating financials and a recent ratings downgrade; avoid.
WHAT'S HAPPENING NOW
Orchid Pharma scheduled an investor roadshow for April 10, 2026. CARE Ratings downgraded Orchid Pharma's long-term facilities to BBB+ from A-.
CORE STORY
Orchid Pharma is being priced as a turnaround play in the API and formulations space, leveraging its existing manufacturing capabilities and export potential.
- Recent price momentum is unsustainable given poor financials.
- Rich valuation (P/E 83.18x) offers no margin of safety.
- CARE Ratings downgrade signals potential financial stress.
- Significant new order wins in API or formulations.
- Successful debt restructuring.
- Substantial improvement in quarterly earnings.
- Micro-cap: Liquidity risk is high.
- Rich valuation: P/E 83.18x vs Industry P/E 31.77x.
- Negative profit growth: Latest Qtr YoY Profit: -121.0%.
DII decreased holdings (Δ -0.39%). FII increased holdings slightly (Δ 0.17%).
India's pharmaceutical sector aims to become a global innovation hub, a potential tailwind.
Profit not consistently converting to cash; Free Cash Flow 5Y: ₹183.13 Cr
The next 2-3 quarters are critical. Orchid Pharma needs to demonstrate significant earnings improvement to justify its valuation. Failure to do so will likely result in a sharp correction.
Primary Thesis Risk
Inability to achieve sustainable profitability will lead to a collapse in valuation.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Orchid Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Orchid Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ORCHPHARMA across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Consistent Growth Track Record (12.51% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (16.91% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (17.39% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (69.84%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (2.12%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.64%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 206.31x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-113.48 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Orchid Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Orchid Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Orchid Pharma LtdOrchid Pharma L...Selected✓ ORCHPHARMA • 524372 | 29.5/100 | ₹986.55₹987 | ₹5595.24₹5595.24 | 206.31Average 206.3 Average | 2.12%Poor 2.12% Poor | 2.64%Poor 2.64% Poor | 0.28Excellent 0.3 Excellent | 17.39%Excellent 17.39% Excellent | 12.51%Good 12.51% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Orchid Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for ORCHPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹19.65 | ₹758.95 | 38.6x |
| FY 2024 | ₹19.06 | ₹1807.05 | 94.8x |
| FY 2023 | ₹11.35 | ₹712.50 | 62.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Orchid Pharma Ltd Quarterly Performance
Latest quarterly metrics for ORCHPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
0.05%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
4.26%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.51%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
17.39%
Compounded annual net profit growth over 5 years
Orchid Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ORCHPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Orchid Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Orchid Pharma Ltd (ORCHPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Orchid Pharma Ltd
About ORCHPHARMA (Orchid Pharma Ltd)
Orchid Pharma Ltd is a dynamic and multifaceted pharmaceutical entity rooted in India, focused on the intricate processes of creating, refining, and distributing a comprehensive ra...nge of pharmaceutical products. The company's core competence lies in the development and manufacturing of active pharmaceutical ingredients (APIs), the very building blocks of effective medications. This expertise extends to the production of finished dosage formulations, encompassing a variety of delivery methods, and also venture into the realm of nutraceuticals, catering to the growing demand for health and wellness products. Orchid Pharma operates with a commitment to quality and precision, ensuring the efficacy and safety of its diverse product portfolio. The company's API product line is particularly robust, showcasing a broad spectrum of therapeutic categories. Orchid Pharma specializes in the production of both oral and injectable cephalosporins, crucial antibiotics used to combat a range of bacterial infections. Furthermore, their portfolio spans human and veterinary applications, demonstrating a commitment to health across species. In addition to cephalosporins, Orchid Pharma manufactures a variety of other antibiotics, including betalactams, macrolides, fluoroquinolones, and imidazoles. This demonstrates their comprehensive approach to tackling infectious diseases and supporting the healthcare needs of a diverse patient population. Orchid Pharma's impact reaches beyond the borders of India, with a significant export presence in approximately 40 countries. This global reach signifies the company's commitment to making essential pharmaceuticals accessible to a wider audience and reflects its adherence to international quality standards. By actively participating in the global pharmaceutical market, Orchid Pharma contributes to advancements in healthcare on a worldwide scale. This dedication to innovation, quality, and accessibility positions Orchid Pharma as a key player in the ever-evolving pharmaceutical landscape.
Company Details
Key Leadership
Corporate Events
ORCHPHARMA Share Price: Frequently Asked Questions
What is the current share price of Orchid Pharma Ltd?
Orchid Pharma Ltd (ORCHPHARMA) trades at ₹986.55 on NSE and BSE. Market cap ₹5.60K (Cr). Educational data only.
What is the P/E ratio of Orchid Pharma Ltd?
Orchid Pharma Ltd has a P/E of 206.31x vs industry average 34.89x.
What is the Bull Run score for Orchid Pharma Ltd?
Orchid Pharma Ltd has a Bull Run score of 29.5/100 based on 25+ financial parameters.
Does Orchid Pharma Ltd pay dividends?
Orchid Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Orchid Pharma Ltd?
Orchid Pharma Ltd has ROE of 2.12%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Orchid Pharma Ltd?
Orchid Pharma Ltd has debt-to-equity of 0.28.
Is Orchid Pharma Ltd a good investment?
Bull Run gives Orchid Pharma Ltd a score of 29.5/100. This is not investment advice — consult a SEBI-registered advisor.